Newsroom
Sorted by: Latest
-
L’essai DISTALS de Rapid Medical™ est extrêmement positif, montrant une reperfusion supérieure avec TIGERTRIEVER™ 13 après un AVC des vaisseaux de moyen calibre
LA NOUVELLE-ORLÉANS et YOKNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, entreprise leader dans le développement de dispositifs endovasculaires actifs, a annoncé aujourd'hui les résultats préliminaires de l'essai multicentrique randomisé contrôlé DISTALS. Ces résultats montrent que le dispositif TIGERTRIEVER™ 13 permet une reperfusion cérébrale supérieure et présente un excellent profil d'innocuité par rapport à la prise en charge médicale des AVC par occlusion des vaisseaux de moyen calibre (O...
-
Riassunto: Il trial DISTALS di Rapid Medical™ riporta risultati straordinariamente positivi, dimostrando la superiorità di riperfusione di TIGERTRIEVER™ 13 nell’ictus dei medi vasi
NEW ORLEANS e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, un’azienda leader nello sviluppo di dispositivi endovascolari attivi, oggi ha annunciato i risultati “late-breaking” del trial clinico controllato, randomizzato e multicentrico DISTALS, che dimostrano che TIGERTRIEVER™ 13 ha ottenuto una riperfusione superiore del tessuto cerebrale, con un eccellente profilo di sicurezza, rispetto alla gestione medica nell’ictus da occlusione dei medi vasi. I risultati sono stati presentati durant...
-
STKL Stock Alert: Halper Sadeh LLC is Investigating Whether SunOpta Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SunOpta Inc. (NASDAQ: STKL) to Refresco for $6.50 per share in cash. Halper Sadeh encourages SunOpta shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether SunOpta and its board of directors violated the federa...
-
RR INVESTOR REMINDER: Richtech Robotics Inc. Investors Have Until April 3, 2026 To Seek Lead Plaintiff Role – Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ:RR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 3, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...
-
AI Sales Platform ACTi Launches to Solve the Sales Hiring Crisis for Businesses
PARAMUS, N.J.--(BUSINESS WIRE)--Genesis Forge of Heroes officially launches Friday, Feb. 6 at 2 p.m. ET during Sean Callagy's Marketing & Sales Process Mastery Live Immersion event, introducing a breakthrough platform that eliminates the sales hiring bottleneck strangling business growth. The launch comes as companies face a critical paradox: laying off thousands of workers while desperately needing more sales capacity. Nowadays 80 percent of companies identify hiring and retaining top sale...
-
Richtech Robotics Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 3, 2026 – Robbins Geller Rudman & Dowd LLP
SAN DIEGO--(BUSINESS WIRE)--The case alleges Richtech Robotics claimed that it had a collaborative and commercial relationship with Microsoft when it did not....
-
Rapid Medical™的DISTALS试验结果极为积极,证实TIGERTRIEVER™ 13对治疗中血管卒中具有卓越的再灌注效果
美国新奥尔良与以色列约克尼姆--(BUSINESS WIRE)--(美国商业资讯)-- 领先的动脉内介入器械开发商Rapid Medical™今日公布了DISTALS多中心随机对照试验的最新突破性结果。该研究显示,在治疗中血管闭塞(MVO)卒中时,TIGERTRIEVER™ 13系统相较于保守治疗能实现更优的脑组织再灌注效果,且具有卓越的安全性。该研究成果已在2026年国际卒中大会(ISC)闭幕主会场进行展示。 顶线结果数据显示,TIGERTRIEVER™ 13组在无症状性颅内出血(sICH)情况下成功再灌注的比例是药物治疗组的3倍——86.3% vs 27.7%(pp < 0.001)。值得注意的是,接受TIGERTRIEVER 13治疗的随机治疗组未报告任何sICH事件。相比之下,仅采用静脉溶栓治疗的sICH发生率更高,在近期临床试验中报告值为2%至6%1,2,3。 “这些结果凸显了当设备和试验均针对远端卒中专门设计时所能实现的突破。”DISTALS研究首席研究员Jeffrey L. Saver医学博士表示,“DISTALS专为远端卒中量身打造,将专为细小脆弱血管设计的装置与...
-
Die DISTALS-Studie von Rapid Medical™ ist äußerst positiv und belegt eine überlegene Reperfusion mit TIGERTRIEVER™ 13 bei Schlaganfällen in mittleren Gefäßen
NEW ORLEANS & YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical™, ein führender Entwickler von aktiven endovaskulären Geräten, hat heute die neuesten Ergebnisse der multizentrischen, randomisierten kontrollierten Studie DISTALS bekannt gegeben, die zeigen, dass TIGERTRIEVER™ 13 im Vergleich zur medizinischen Behandlung bei Schlaganfällen mit mittlerer Gefäßokklusion (MVO) eine überlegene Reperfusion des Hirngewebes mit einem ausgezeichneten Sicherheitsprofil erzielt. Die Ergebnisse wurden in der...
-
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study and highlighted new findings related to the VARIPULSE Platform....
-
Glancy Prongay Wolke & Rotter Scores Top Securities Settlement of 2025
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (GPWR) is proud to announce that the Firm, as sole lead counsel for Alibaba investors, attained the highest securities class action settlement of 2025, according to prominent national economic consulting firm, NERA. Spearheaded by partners Kara Wolke and Melissa Wright, GPWR leveraged its deep experience and tenacious advocacy into a $433.5 million settlement for the benefit of Alibaba’s investors. Injured by fraud or corporate...